TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6418094

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) + Nifedipine (30 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol (80 mg/day) + Placebo (3 tablets/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol (80 mg/day) + Placebo (3 tablets/day) during Phase II
Number of subjects: 10
Study: 30188363

Group type: EXPERIMENTAL
Intervention: BFRRE (Blood Flow-Restricted Resistance Exercise)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional training (Con)
Number of subjects: 17
Study: 29061084

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with resistance adjusted to 30% of maximal inspiratory pressure, 90 breaths a day, 5 times a week for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (regular physical therapy)
Number of subjects: 30
Study: 26577065

Group type: EXPERIMENTAL
Intervention: 10mg oral pure THCV administered daily for five days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1mg intravenous THC administered on the fifth day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo administered daily for five days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: THC under THCV condition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: THCV in combination with THC
Number of subjects: 10
Study: 24438504

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with sorafenib (800 mg daily) and transcatheter arterial infusion (TAI) with cisplatin (65 mg/m2/cycle)
Number of subjects: 20
Study: 20443800

Group type: EXPERIMENTAL
Intervention: Resilient liner attachment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clip attachment
Number of subjects: 30
Study: 18678161

Group type: EXPERIMENTAL
Intervention: Shu-needling therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine needling method
Number of subjects: 102
Study: 15951542

Group type: EXPERIMENTAL
Intervention: Mesalazine enema (1 g at bedtime)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 127
Study: 12700159

Group type: EXPERIMENTAL
Intervention: Continuous feeding with a mixed nutrient drink for 10 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasting for 22 hours
Number of subjects: 12
Study: 11035610

Group type: EXPERIMENTAL
Intervention: DNA PCR
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: RNA PCR
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Viral load of RNA-positive specimens
Number of subjects: 395
Study: 8852905

Group type: EXPERIMENTAL
Intervention: 5-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV)
Number of subjects: 60
Study: 1642935

Group type: EXPERIMENTAL
Intervention: IV diclofenac 2 mg kg‐1/24 h for 2 days
Number of subjects: 30
Study: 6377959

Group type: EXPERIMENTAL
Intervention: Oral controlled‐release morphine (MST 30 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30771622

Group type: EXPERIMENTAL
Intervention: Focused attention on speech stream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diverted attention from speech stream
Number of subjects: 0
Study: 29346221

Group type: EXPERIMENTAL
Intervention: Simulation-based training course
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Expert physicians
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PALS global performance score
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PALS checklist score
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ESM checklist score
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ESM global performance score
Number of subjects: 18
Study: 28134943

Group type: EXPERIMENTAL
Intervention: Gum chewing (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard postoperative recovery (n = 32)
Number of subjects: 64
Study: 24533522

Group type: EXPERIMENTAL
Intervention: Cluster-set (CS) protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditional set (TS) protocol
Number of subjects: 11
Study: 22243564

Group type: EXPERIMENTAL
Intervention: Aleurone-rich cereal products (27 g aleurone/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control products balanced for fibre and macronutrients
Number of subjects: 79
Study: 20371148

Group type: EXPERIMENTAL
Intervention: Sports Climbing (SC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Yoga)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Sports Climbing)
Number of subjects: 20
Study: 18581941

Group type: EXPERIMENTAL
Intervention: Albuterol (ALB, 16 mg x d(-1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA, lactose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Albuterol (ALB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study: 15754176

Group type: EXPERIMENTAL
Intervention: Mirror (viewing a mirror‐reflection of the active hand)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active (viewing the active hand)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Central (viewing a mark positioned between hands)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inactive (viewing the inactive hand)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest (both hands at rest)
Number of subjects: 8
Study: 12685519

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study: 10204564

Group type: EXPERIMENTAL
Intervention: Cadaver model training
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bench model training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Text learning
Number of subjects: 23
Study: 7604951

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral terfenadine 60 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral astemizole 10 mg once daily
Number of subjects: 0
Study: 2113796

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg orally
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 200
Study: 360846

Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.1%, 0.25%, and 0.5%)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Epinephrine hydrochloride (0.5%, 1.0%, 2.0%)
Number of subjects: 36
Study: 31337378

Group type: EXPERIMENTAL
Intervention: Childhood adversity (≥2 types of events)
Number of subjects: 115
Study: 28272337

Group type: EXPERIMENTAL
Intervention: Isotonic beverage (IB)
Number of subjects: 49
Study: 25662861

Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogenosulfate (CHS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clopidogrel besylate (CB)
Number of subjects: 101
Study: 24396214

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation training
Number of subjects: 30
Study: 21398419

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 18441772

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% (n=578)
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Vehicle gel (n=547)
Number of subjects: 1306
Study: 16959675

Group type: EXPERIMENTAL
Intervention: Physical training 5 days a week for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 39
Study: 14514389

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg bid for 14 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no treatment influencing prolactin or other sexual hormones)
Number of subjects: 68
Study: 10611136

Group type: EXPERIMENTAL
Intervention: Methoxsalen (50 mg oral)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 11
Study: 9088818

Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5, 1, 2, and 4 micrograms kg‐1 min‐1 for 40 min each
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopexamine 4 micrograms kg‐1 min‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopexamine and Placebo
Number of subjects: 20
Study: 7978422

Group type: EXPERIMENTAL
Intervention: GOD‐F method
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hexokinase method
Number of subjects: 48
Study: 2524549

Group type: EXPERIMENTAL
Intervention: MSD recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: SKF recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Number of subjects: 201

Group type: COMPARATOR
Intervention: MSD plasma-derived vaccine (2 micrograms doses, 3 doses I.M. at 0, 1, 2 months)
Number of subjects: 201
Study: 1201630

Group type: EXPERIMENTAL
Intervention: Twice weekly dose-fractionation (12 fractions in 28 days)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Thrice weekly dose-fractionation (6 fractions in 18 days)
Number of subjects: 411
Study: 31160251

Group type: EXPERIMENTAL
Intervention: Group A: ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, two cycles every 3 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Group B: ipilimumab 1 mg/kg plus nivolumab 3 mg/kg, two cycles every 3 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Group C: ipilimumab 3 mg/kg for two cycles every 3 weeks followed by nivolumab 3 mg/kg for two cycles every 2 weeks
Number of subjects: 89
Study: 29381993

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg in 98 mL saline for 20 minutes after induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (100 mL saline)
Number of subjects: 100
Study: 26474380

Group type: EXPERIMENTAL
Intervention: Telephone consultation between pain specialist and primary care physician
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care by primary care physician
Number of subjects: 80
Study: 23874094

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime 250 mg twice daily for mild-moderate exacerbation or 500 mg twice daily for severe exacerbation for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 0
Study: 21208909

Group type: EXPERIMENTAL
Intervention: F4 protein (10, 30, or 90 μg/dose) adjuvanted with AS01
Number of subjects: 180

Group type: COMPARATOR
Intervention: F4 protein (10, 30, or 90 μg/dose) reconstituted with water for injection
Number of subjects: 180
Study: 19805690

Group type: EXPERIMENTAL
Intervention: Flow cytometric measurement of minimal residual disease (MRD) at day 15 of induction therapy
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Flow cytometric measurement of MRD
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: PCR MRD
Number of subjects: 830
Study: 17426059

Group type: EXPERIMENTAL
Intervention: GVD regimen (gemcitabine 1000 mg/m², vinorelbine 20 mg/m², pegylated liposomal doxorubicin 15 mg/m² for transplant-naive patients; gemcitabine 800 mg/m², vinorelbine 15 mg/m², pegylated liposomal doxorubicin 10 mg/m² for post-transplant patients)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GVD regimen followed by autologous transplant in transplant-naive patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GVD regimen in patients with prior transplant failure
Number of subjects: 91
Study: 15525924

Group type: EXPERIMENTAL
Intervention: IA morphine with bupivacaine injected 10 minutes before tourniquet release
Number of subjects: 40

Group type: COMPARATOR
Intervention: IA morphine with bupivacaine injected after tourniquet release
Number of subjects: 40
Study: 11494074

Group type: EXPERIMENTAL
Intervention: 5 mg vardenafil
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study: 8922361

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 0
Study: 1359998

Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terbutaline 500 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4011338

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (30 mg/kg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 22
Study: 30556372

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 36

Group type: COMPARATOR
Intervention: NaF/triclosan dentifrice
Number of subjects: 36
Study: 30289905

Group type: EXPERIMENTAL
Intervention: Four coaching sessions after communication skills training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single coaching session (control group)
Number of subjects: 72
Study: 26655431

Group type: COMPARATOR
Intervention: Physical activity and nutrition intervention delivered through 12 home visits and up to 12 phone calls over 12 months.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition intervention
Number of subjects: 151
Study: 24802283

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + connective tissue graft (CAF + CTG) with labial submucosal tissue (LST) removal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Coronally advanced flap + connective tissue graft (CAF + CTG) without LST removal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-operative morbidity evaluation
Number of subjects: 50
Study: 22504214

Group type: EXPERIMENTAL
Intervention: Disposable Pressure Right acupressure device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acustimulation device
Number of subjects: 100
Study: 19459989

Group type: EXPERIMENTAL
Intervention: Continuous HAART
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intermittent HAART
Number of subjects: 69
Study: 17201879

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg p.o. twice daily for 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 70
Study: 15007536

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12355944

Group type: EXPERIMENTAL
Intervention: Gemcitabine or its combination therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 0
Study: 9718247

Group type: EXPERIMENTAL
Intervention: Nortriptyline (titrated to 50-150 ng/ml)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 78
Study: 7817271

Group type: EXPERIMENTAL
Intervention: Hypoxyradiotherapy (acute hypoxia)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 165
Study: 2113874

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension
Number of subjects: 660

Group type: COMPARATOR
Intervention: Amoxycillin syrup
Number of subjects: 660
Study: 460026

Group type: EXPERIMENTAL
Intervention: Etozolin (800 mg p.o.)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Furosemide (80 mg p.o.)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Etozolin (800 mg p.o.) and Furosemide (80 mg p.o.)
Number of subjects: 115
Study: 30995635

Group type: EXPERIMENTAL
Intervention: Whitening procedure and randomized SVD approximation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Tikhonov regularization with nonnegativity constraint
Number of subjects: 0
Study: 27744012

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT, 2×/wk)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Jump Training (JUMP, 3×/wk)
Number of subjects: 38
Study: 25510307

Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Health Education (HE) control
Number of subjects: 49
Study: 22917075

Group type: EXPERIMENTAL
Intervention: Enriched cheese (90 g/d for 3 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control cheese (90 g/d for 3 weeks)
Number of subjects: 42
Study: 20802006

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m(2) on days 1 and 29, Irinotecan 60 mg/m(2) on days 1, 8, 15, 29, 36, and 43, and 30 mg/m(2) on days 57, 64, 71, 78, 85 and 92, followed by thoracic radiotherapy starting on day 57 at 2 Gy/day (total 60 Gy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin and Irinotecan regimen
Number of subjects: 68
Study: 19027265

Group type: EXPERIMENTAL
Intervention: Posterior cruciate-retaining design
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized design
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Variable joint line elevation
Number of subjects: 200
Study: 17049894

Group type: EXPERIMENTAL
Intervention: Tulo+Tio (tiotropium added to tulobuterol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tulo (tulobuterol alone)
Number of subjects: 60
Study: 14724301

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1314
Study: 11318046

Group type: EXPERIMENTAL
Intervention: Auditory metronome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual metronome
Number of subjects: 0
Study: 9394979

Group type: EXPERIMENTAL
Intervention: Topically applied PAF antagonist (RO‐24‐0238)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 36
Study: 8186880

Group type: EXPERIMENTAL
Intervention: Biphasic waveform defibrillation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Monophasic waveform defibrillation
Number of subjects: 14
Study: 2834148

Group type: EXPERIMENTAL
Intervention: Pancreatic duct occlusion (PDO) during Whipple's operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whipple's operation without PDO
Number of subjects: 0
Study: 29422189

Group type: EXPERIMENTAL
Intervention: Mindfulness Skills for Students (MSS)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Support as usual
Number of subjects: 616
Study: 27762662

Group type: EXPERIMENTAL
Intervention: Caffeine (1.5‐3.0 mg · kg‐1 day‐1; titrated)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (postcaf: 358.0 ± 89.8 kJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (postcaf: 351.8 ± 49.4 kJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine and Placebo
Number of subjects: 18
Study: 26142555

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 110
Study: 22556317

Group type: EXPERIMENTAL
Intervention: Spontaneous (S) mode
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spontaneous/timed (S/T) modes (low BURR and high BURR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low BURR (S/T mode)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High BURR (S/T mode)
Number of subjects: 10
Study: 20805430

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3237

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3237
Study: 18279051

Group type: EXPERIMENTAL
Intervention: Zinc lozenges (13.3 mg of zinc as zinc acetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15689918

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone (T) + letrozole (Lz; 2.5 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-dose testosterone (T) + placebo (P)
Number of subjects: 23
Study: 14620222

Group type: EXPERIMENTAL
Intervention: Cell phone conversation during the task
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Talking to someone in the same room
Number of subjects: 45

Group type: COMPARATOR
Intervention: No distractions (Control group)
Number of subjects: 45
Study: 10501791

Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg daily
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 8548515

Group type: EXPERIMENTAL
Intervention: 6‐item Philadelphia Geriatric Center Affect Rating Scale
Number of subjects: 296
Study: 1985428

Group type: EXPERIMENTAL
Intervention: Dietary control of blood phenylalanine below 900 mumol/L maintained beyond age 10 years
Number of subjects: 95

Group type: COMPARATOR
Intervention: Dietary control not maintained (blood phenylalanine persistently above 900 mumol/L)
Number of subjects: 95
Study: 6320622

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 13
Study: 31780139

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block with sugammadex reversal
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate neuromuscular block with neostigmine reversal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative shoulder pain
Number of subjects: 100
Study: 31166471

Group type: EXPERIMENTAL
Intervention: Hydraulic pressure delivery system (HPDS) with high-viscosity cement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon tamp system (BTS) with high-viscosity cement
Number of subjects: 0
Study: 28538314

Group type: EXPERIMENTAL
Intervention: Neuromuscular dentistry‐designed mouthguard (NMDD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Over-the-counter boil-and-bite mouthguard (BB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No mouthguard (NO)
Number of subjects: 42
Study: 25895948

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24314842

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control
Number of subjects: 226